Welcome to Sequella

Sequella is a clinical stage antiinfectives company focused on discovering, developing, and commercializing improved treatments for serious infectious diseases. The company leverages its global influence, R&D platforms and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships with global pharmaceuticals and NGO's, Sequella is working to commercialize a broad product portfolio designed to treat infectious disease threats with significant market opportunity.

Sequella's growth strategy leverages a strong management team and core competencies in chemistry, microbiology, molecular biology, infectious diseases, and product development. The company's product portfolio addresses disease areas of known or suspected infectious etiology:

Mycobacterium tuberculosis infections including drug-suceptible TB, multi drug-resistant TB (MDR-TB), and extremely drug-resistant TB (XDR-TB) indications (SQ109, SQ609, Biological System for Molecular Antibiotic Resistance Testing (known as B-SMART™).

Helicobacter pylori infections (SQ109)

Gastric and duodenal ulcers, and gastric cancer indications

Clostridium difficile infections (SQ641)

Life-threatening diarrhea

M. avium paratuberculosis and other nontuberculous mycobacterial infections (SQ641)

Crohn's Disease and Buruli ulcer indications